New potential antitumoral di(hetero)arylether derivatives in the thieno[3,2-b]pyridine series : synthesis and fluorescence studies in solution and in nanoliposomes by Queiroz, Maria João R. P. et al.
  1
New potential antitumoral di(hetero)arylether derivatives in the 
thieno[3,2-b]pyridine series: synthesis and fluorescence studies in 
solution and in nanoliposomes 
 
Maria-João R. P. Queiroz,a,* Sofia Dias,a Daniela Peixoto,a Ana Rita O. Rodrigues,b Andreia 
D. S. Oliveira,b Paulo J. G. Coutinho,b Luís A. Vale-Silva,c,d Eugénia Pinto,c,d Elisabete M. S. 
Castanheirab,* 
 
aDepartamento/Centro de Química, Universidade  do Minho, Campus de Gualtar, 4710-057 Braga, Portugal 
bCentro  de Física (CFUM), Universidade do Minho, Campus de Gualtar, 4710-057 Braga, Portugal 
cLaboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de Farmácia da Universidade 
do Porto, Rua Aníbal Cunha 164, 4050-047 Porto, Portugal 
dCEQUIMED-UP, Centro de Química Medicinal da Universidade do Porto, Rua Aníbal Cunha 164, 4050-047 
Porto, Portugal. 
_________________________________________________________________________ 
Abstract 
New fluorescent methoxylated di(hetero)arylethers in the thieno[3,2-b]pyridine series were prepared  
by a copper-catalyzed Ullmann-type C-O coupling of the methyl 3-amino-6-bromothieno[3,2-
b]pyridine-2-carboxylate with ortho, meta and para-methoxyphenols, using N,N-dimethylglycine as 
the ligand and Cs2CO3 as the base. The compounds obtained were tested for their inhibitory growth 
activity in three human tumor cell lines MCF-7 (breast adenocarcinoma), A375-C5 (melanoma), NCI-
H460 (non-small cell lung cancer). The di(hetero)arylethers bearing a methoxy group in the ortho and 
meta positions showed very low GI50 values (1.1−2.5 µM) in all the three tumor cell lines. Their 
fluorescence properties in solution and when encapsulated in different nanoliposome formulations, 
composed either by egg-yolk phosphatidylcholine (Egg-PC), dipalmitoyl phosphatidylcholine (DPPC), 
dimyristoyl phosphatidylglycerol (DMPG), dioctadecyldimethylammonium bromide (DODAB), 
distearoyl phosphatidylcholine (DSPC), with or without cholesterol (Ch), or distearoyl 
phosphatidylethanolamine-(polyethylene glycol)2000 (DSPE-PEG), were studied. All compounds can 
be carried in the hydrophobic region of the liposome membrane. The liposomes with incorporated 
compounds are nanometric in size (diameter lower than 150 nm) and have generally low 
polydispersity.  
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1. Introduction 
Thienopyridine derivatives including di(hetero)arylethers have attracted much attention 
because of their potential different biological activities namely as antitumoral agents [1], 
nonreceptor Src kinase inhibitors [2] and receptor tyrosine kinase inhibitors [3,4,5].  
Nanoliposomes are new technological developments for the encapsulation and delivery of 
bioactive agents. Because of their biocompatibility and biodegradability, along with their size, 
nanoliposomes have potential applications in a vast range of fields, including nanotherapy. 
Nanoliposomes are able to enhance the performance of bioactive agents by improving their 
bioavailability, in vitro and in vivo stability, as well as preventing their unwanted interactions 
with other molecules [6]. They may contain, in addition to phospholipids, other molecules 
such as cholesterol (Ch) which is an important component of most natural membranes. The 
incorporation of Ch may increase the stability by modulating the fluidity of the lipid bilayer 
preventing crystallization of the phospholipid acyl chains and providing steric hindrance to 
their movement. Further advances in liposome research found that polyethylene glycol (PEG), 
which is inert in the body, allows longer circulatory life of the drug delivery system [7].  
In this work we describe the synthesis of new fluorescent di(hetero)arylethers in the 
thieno[3,2-b]pyridine series, by copper-catalyzed Ullmann-type C-O coupling of the methyl 
3-amino-6-bromo-thieno[3,2-b]pyridine-2-carboxylate, earlier prepared by us [8], with o-, m- 
and p-methoxyphenols. The effects of the three coupling products obtained in the growth 
inhibition of human tumor cell lines, MCF-7 (breast adenocarcinoma), A375-C5 (melanoma), 
NCI-H460 (non-small cell lung cancer), were evaluated and the ortho and meta-
methoxydi(hetero)arylethers were shown to be the most promising antitumor compounds, 
presenting very low GI50 values in all the cell lines studied. For the latter compounds, the 
fluorescence properties were evaluated in different solvents and when encapsulated in 
different nanoliposome formulations, with or without cholesterol and PEG. Fluorescence 
anisotropy measurements can give relevant information about the compound behavior and 
location in the several liposomes, namely if they are located in the lipid bilayer, feeling the 
differences between the gel and the liquid-crystalline phases of phospholipids. These studies 
are important keeping in mind future drug delivery applications of these new potential 
anticancer drugs. 
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2. Experimental 
2.1. Synthesis 
2.1.1.General Remarks  
Melting points (oC) were determined in a SMP3 Stuart apparatus and are uncorrected. 1H 
and 13C NMR spectra were recorded on a Bruker Avance III at 400 and 100.6 MHz, 
respectively. Heteronuclear correlations, 1H-13C, HMQC or HSQC were performed to 
attribute some signals.  
MS and HRMS data were recorded using a method of direct injection by EI (70eV) and by 
the mass spectrometry service of the University of Vigo, Spain.  
The reactions were monitored by thin layer chromathography (TLC) in aluminium plates 
covered with a layer of silica gel 60 (Macherey-Nagel) of 0.2 mm, with UV254 fluorescence 
indicator. Column chromatography was performed on Macherey-Nagel silica gel 230-400 
mesh, using a solvent gradient, increasing the polarity in mixtures of diethylether/ petroleum 
ether in portions of 10% of diethylether until product isolation. Petroleum ether refers to the 
boiling range 40-60 oC. 
 
2.1.2. General procedure for the copper-catalyzed C-O (Scheme 1): In a Schlenk tube, dry 
dioxane (3 mL),  CuI (10 mol%), N,N-dimethylglycine (30 mol%), the corresponding phenol 
(1.3 equiv.), Cs2CO3 (2.0 equiv.) and methyl 3-amino-6-bromothieno[3,2-b]pyridine-2-
carboxylate (1), were added under argon, and the mixture was heated with stirring at 110 oC 
for 8 hours. After cooling, NaOH aqueous (30% w/v) and ethyl acetate were added. The 
phases were separated, the organic phase was dried (MgSO4) and filtered. The solvent was 
evaporated under reduced pressure giving a solid which was submitted to column 
chromatography. 
 
2.1.2.1. Methyl 6-(2-methoxyphenoxy)-3-aminothien[3,2-b]pyridine-2-carboxylate (2a): 
Thieno[3,2-b]pyridine 1 (150 mg, 0.545 mmol) and 2-methoxyphenol (1.3 equiv, 0.1 mL, 
0.709 mmol), were heated  and the reaction mixture was treated according to the general 
procedure. Column chromatography  using 60% diethylether/petroleum ether gave compound 
2a as a yellow solid (67.0 mg, 40%), m.p. 137-139 oC, after some washes with petroleum 
ether. 1H NMR (CDCl3, 400 MHz): δ 3.81 (3H, s, OMe), 3.89 (3H, s, OMe), 6.21 (2H, s 
largo, NH2), 6.99-7.01 (1H, m, Ar-H), 7.06 (1H, dd, J = 8.4 e 1.6 Hz, ArH), 7.12 (1H, dd, J = 
8.0 e 1.6 Hz, ArH), 7.24-7.38 (1H, m, Ar-H), 7.34 (1H, d, J = 2.4 Hz, HetAr), 8.46 (1H, d, J = 
2.4 Hz, HetAr) ppm. 13C NMR (CDCl3, 100.6 MHz): δ 51.55 (OMe), 55.85 (OMe), 98.17 (C), 
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113.07 (CH), 116.11 (CH), 121.41 (CH), 122.07 (CH), 126.49 (CH), 135.33 (C), 138.54 
(CH), 141.22 (C), 143.15 (C), 147.38 (C), 151.45 (C), 154.46 (C), 165.30 (C=O) ppm. MS 
(EI) m/z (%): 330.07 (M+,100), 298.04 (M+-OMe, 69). HRMS M+ calcd. for C16H14N2O4S: 
330.0674, found 330.0680. 
 
2.1.2.2. Methyl 6-(3-methoxyphenoxy)-3-aminothieno[3,2-b]pyridine-2-carboxylate (2b): 
Thieno[3,2-b]pyridine 1 (150 mg, 0.545 mmol) and 3-methoxyphenol (1.3 equiv, 0.1 mL, 
0.709 mmol), were heated and the reaction mixture was treated according to the general 
procedure. Column chromatography using 40% diethylether/petroleum ether gave compound 
2b as a yellow solid (96.0 mg, 53%), m.p. 111-112 oC, after some washes with petroleum 
ether. 1H NMR (CDCl3, 400 MHz): δ 3.81 (3H, s, OMe), 3.90 (3H, s, OMe), 6.21 (2H, s 
largo, NH2), 6.63-6.66 (2H, m, ArH), 6.74-6.77 (1H, m, ArH), 7.27-7.32 (1H, m, ArH), 7.53 
(1H, d, J = 2.4 Hz, HetArH), 8.45 (1H, d, J = 2.4 Hz, HetAr) ppm. 13C NMR (CDCl3, 100.6 
MHz): δ 51.56 (OMe), 55.44 (OMe), 98.60 (C), 105.54 (CH), 110.28 (CH), 111.38 (CH), 
118.41 (CH), 130.61 (CH), 135.18 (C), 139.89 (CH), 142.02 (C), 147.34 (C), 153.48 (C), 
156.48 (C), 161.23 (C), 165.24 (C=O) ppm. MS (EI) m/z(%): 330.07 (M+,100), 298.04 (M+-
OMe, 67), HRMS M+ calcd. for C16H14N2O4S: 330.0674, found 330.0675. 
 
2.1.2.3. Methyl 6-(4-methoxyphenoxy)-3-aminothieno[3,2-b]piridine-2-carboxylate (2c): 
Thieno[3,2-b]pyridine 1 (100 mg, 0.363 mmol) and 4-methoxyphenol (1.0 equiv, 44.0 mg, 
0,363 mmol), were heated and the reaction mixture was treated according the general 
procedure. Column chromatography using 50% diethylether/petroleum ether gave compound 
2c as a yellow solid  (79.0 mg, 65%), m.p. 129-131 oC, after some washes with petroleum 
ether. 1H NMR (CDCl3, 400 MHz): δ 3.84 (3H, s, OMe), 3.90 (3H, s, OMe), 6.27 (2H, s 
largo, NH2), 6.95 (2H, d, J = 9.2 Hz, 2xArH), 7.05 (2H, d, J = 9.2 Hz, 2xArH), 7.44 (1H, d, J 
= 2.4 Hz, HetArH), 8.44 (1H, d, J = 2.4 Hz, HetArH) ppm. 13C NMR (CDCl3, 100.6 MHz): δ 
51.55 (OMe), 55.68 (OMe), 98.29 (C), 115.29 (2×CH), 116.64 (CH), 121.21 (2×CH), 135.29 
(C), 139.31 (CH), 141.44 (C), 147.41 (C), 148.65 (C), 154.90 (C), 158.84 (C), 165.30 (C=O) 
ppm. MS (EI) m/z(%): 330.07 (M+,100), 298.04 (M+-OMe, 68), HRMS M+ calcd. for 
C16H14N2O4S: 330.0674, found 330.0671. 
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2.2. Biological Activity 
2.2.1. Reagents 
Fetal bovine serum (FBS), L-glutamine, phosphate buffered saline (PBS) and trypsin were 
from Gibco Invitrogen Co. (Scotland, UK). RPMI-1640 medium was from Cambrex (New 
Jersey, USA). Acetic acid, dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin, 
ethylenediaminetetraacetic acid (EDTA), sulforhodamine B (SRB) and trypan blue were from 
SigmaChemical Co. (Saint Louis, USA). Tricloroacetic acid (TCA) and Tris were sourced 
from Merck (Darmstadt, Germany). 
 
2.2.2. Solutions of the compounds 
Stock solutions of the tested compounds were prepared in DMSO and kept at −70°C. 
Appropriate dilutions were freshly prepared in the test medium just prior to the assays. The 
effect of the vehicle solvent (DMSO) on the growth of the cell lines was evaluated by 
exposing untreated control cells to the maximum concentration of DMSO used in the assays 
(0.25%). No influence was found (data not shown). 
 
2.2.3. Cell cultures 
Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell 
lung cancer) and A375-C5 (melanoma) were used. MCF-7 and A375-C5 were obtained from 
the European Collection of Cell Cultures (ECACC, Salisbury, UK), and NCI-H460 was 
kindly provided by the National Cancer Institute (NCI, Bethesda, USA). They were routinely 
maintained as adherent cell cultures in RPMI-1640 medium supplemented with 5% heat-
inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 U/mL, streptomycin 100 
µg/mL), at 37°C in a humidified atmosphere containing 5% CO2. Exponentially growing cells 
were obtained by plating 1.5×105 cells/mL for MCF-7 and 0.75×105 cells/mL for A375-C5 
and NCI-H460, followed by a 24 h incubation. 
 
2.2.4. Cell growth inhibition assay 
The effects on the in vitro growth of human tumor cell lines were evaluated according to the 
procedure adopted by the NCI (USA) in their “In vitro Anticancer Drug Discovery Screen”, 
using the protein-binding dye sulforhodamine B to assess cell growth [9,10]. Briefly, 
exponentially growing cells were exposed for 48 h, in 96-well microtiter plates, to five serial 
dilutions of each test compound, starting from a maximum concentration of 150 µM (if 
possible). Following the exposure period adherent cells were fixed in situ, washed and stained 
  6
with SRB. The bound stain was solubilized and the absorbance was measured at 492 nm in a 
plate reader (Biotek Instruments Inc., Powerwave XS, Wincoski, USA). Dose-response curves 
were obtained for each test compound and cell line, and the growth inhibition of 50% (GI50), 
corresponding to the concentration of the compounds that inhibited 50% of the net cell growth 
was calculated as described elsewhere [10]. Doxorubicin was tested in the same manner to be 
used as a positive control. 
 
2.3. Liposomes preparation 
All the solutions were prepared using spectroscopic grade solvents and ultrapure water 
(Milli-Q grade). 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC), 1,2-diacyl-sn-glycero-3-phosphocholine from egg yolk 
(egg-PC), 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt) (DMPG) 
and cholesterol (Ch) were obtained from Sigma-Aldrich. 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(poly-ethylene glycol)-2000] (ammonium salt) (DSPE-
PEG) was obtained from Avanti Polar Lipids, while dioctadecyldimethylammonium bromide 
(DODAB) was from Tokyo Kasei (lipid structures are shown below). 
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Nanoliposomes were prepared by evaporation of a mixture of lipids and compound in 
chloroform under vacuum for 12 h. The lipid/compound film was then hydrated with an 
aqueous buffer solution (10 mM Tris-HCl buffer, pH=7.4), above the lipids melting transition 
temperature (ca. 41 ºC for DPPC [11], 23 ºC for DMPG [12], 55 ºC for DSPC [13] and 45 ºC 
for DODAB [14]), followed by six extrusion cycles (using a LIPEXTM extruder) through 100 
nm polycarbonate membranes. Between the extrusion cycles, the solutions were allowed to 
equilibrate for 1 h. The final total lipid concentration was 1 mM, with a compound/lipid molar 
ratio of 1:333.  
 
DLS and zeta potential measurements: Liposomes mean diameter and size distribution 
(polydispersity index) were measured using a Dynamic Light Scattering (DLS) equipment 
(NANO ZS Malvern Zetasizer), at 25 ºC, using a He-Ne laser of 633 nm and a detector angle 
of 173º. Five independent measurements were performed for each sample. Malvern 
Dispersion Technology Software (DTS) was used with multiple narrow mode (high 
resolution) data processing, and mean size (nm) and error values were considered. 
 
2.4. Spectroscopic measurements 
 Absorption spectra were recorded in a Shimadzu UV-3101PC UV-Vis-NIR 
spectrophotometer. Fluorescence measurements were performed using a Fluorolog 3 
spectrofluorimeter, equipped with double monochromators in both excitation and emission, 
Glan-Thompson polarizers and a temperature controlled cuvette holder.  Fluorescence spectra 
were corrected for the instrumental response of the system.  
For fluorescence quantum yield determination, the solutions were previously bubbled for 
20 minutes with ultrapure nitrogen. The fluorescence quantum yields (Φs) were determined 
using the standard method (equation 1) [15,16]. Quinine sulfate in H2SO4 0.05 M was used as 
reference, Φr = 0.546 at 25 ºC [17]. 
    ( ) ( )[ ] r2rrs2ssrs Φ=Φ nFAnFA      (1) 
where A is the absorbance at the excitation wavelength, F the integrated emission area and n 
the refraction index of the solvents used. Subscripts refer to the reference (r) or sample (s) 
compound. The absorbance value at excitation wavelength was always less than 0.1, in order 
to avoid inner filter effects. 
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Solvatochromic shifts can be described by the Lippert-Mataga equation (2), which relates 
the energy difference between absorption and emission maxima to the orientation 
polarizability, [18,19] 
constf
hcR
+∆µ∆
piε
=ν−ν 3
2
flabs
2
4
1
0
          (2) 
where absν  is the wavenumber of maximum absorption, flν  is the wavenumber of maximum 
emission, ∆µ = µe – µg is the difference in the dipole moment of solute molecule between 
excited (µe) and ground (µg) states, R is the cavity radius (considering the fluorophore a point 
dipole at the center of a spherical cavity immersed in the homogeneous solvent), and f∆  is 
the orientation polarizability given by (eq. 3): 
12
1
12
1
2
2
+
−
−
+ε
−ε
=∆
n
nf   ,            (3)  
where ε is the static dielectric constant and n the refractive index of the solvent.  
An alternative expression, proposed by Bakhshiev, takes into account the angle, γ, between 
the ground and excited state dipole moments of the fluorophore [20,21]:   
( ) ( ) constnf
hcR
+εµ+γµµ−µ
piε
=ν−ν ,cos22
4
1 2
eeg
2
g3flabs
0
  (4) 
where 2eeg
2
g cos2 µ+γµµ−µ  is equivalent to 
2
ge µ−µ
rr
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  ( )
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=ε
n
n
nf       (5) 
The steady-state fluorescence anisotropy, r, is calculated by 
          
VHVV
VHVV
2 IGI
IGI
r
+
−
=
            (6) 
where IVV and IVH are the intensities of the emission spectra obtained with vertical and 
horizontal polarization, respectively (for vertically polarized excitation light), and 
HHHV IIG =  is the instrument correction factor, where IHV and IHH are the emission 
intensities obtained with vertical and horizontal polarization (for horizontally polarized 
excitation light). 
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3. Results and discussion 
3.1. Synthesis 
New di(heteroaryl)ethers 2a-c were prepared by copper-catalyzed C-O coupling of the 
methyl 3-amino-6-bromothieno[3,2-b]pyridine-2-carboxylate (1), earlier prepared by us [8], 
with ortho, meta and para-methoxyphenols, using CuI as the catalyst,  N,N-dimethylglycine 
as the ligand and Cs2CO3 as the base, in moderate to good yields (Scheme 1). 
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i
i) CuI (10mol%), N,N-dimethylglycine (30mol%),
Cs2CO3 (2 equiv.), dry dioxane, 110 oC, Ar, 8h.
 
Scheme 1. Synthesis of di(hetero)arylethers 2a-c by copper-catalyzed C-O coupling 
 
 
The Ullmann ether synthesis has been extensively used for the formation of diarylethers 
[22,23]. However, the harsh reaction conditions (125-220 oC in neat phenol or solvents such 
as pyridine collidine or N,N-dimethylformamide), the usual requirement for stoichiometric (or 
higher) quantities of copper, and the fact that unactivated aryl halides usually react in low 
yields have limited the utility of this reaction [22]. Thus, development of methods for the 
synthesis of diarylethers under relatively mild conditions is receiving increasing interest. Ma 
and Cai reported for the first time in 2003 that, under the action of N,N-dimethylglycine as the 
ligand, CuI-catalyzed coupling reaction of aryl halides and phenols using Cs2CO3 as the base, 
could be carried out at 90 oC to give the corresponding diarylethers [24]. As described for the 
amino acid promoted CuI-catalyzed C-N bond formation from aryl halides and amines or N-
containing heterocycles, the mechanism for the formation of the diarylethers (C-O bond 
formation) may occur through two pathways:1) oxidative addition/reductive elimination; 2) π-
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complex mechanism. Based on the fact that copper ions can form chelates with amino acids 
through the carboxyl and amino groups, Ma et al. put forward two possible catalytic cycles 
[25]. 
 
3.2. Biological activity 
The effects of the di(hetero)arylethers 2a-c on the human tumor cells growth were evaluated 
in three human tumor cell lines MCF-7 (breast adenocarcinoma), A375-C5 (melanoma), NCI-
H460 (non-small cell lung cancer) and the results are presented in Table 1. The 
di(hetero)arylethers bearing a methoxy group in the ortho and meta positions 2a and 2b, 
respectively, are the most promising antitumor compounds presenting very low GI50 values 
(1.1-2.5 µM) in the tumor cell lines in study. The position of the methoxy group is very 
important for the activity, since compound 2c with the methoxy group in the para position 
relative to the ether function, presented very much higher GI50 values. 
Doxorubicin, used as positive control, presents very high citotoxicity in these cell lines but 
it is also very toxic for the human body and nowadays is used in a liposomal pegylated 
formulation that decreases their toxicity and adverse secundary effects and increases the 
captation by the tumor [26-28]. 
 
Table 1. Growth inhibitory activity of the di(hetero)arylethers 2a-c on the three human tumor cell lines in study. 
Compounds GI50 (µM)
 a
 
MCF-7 A375-C5 NCI-H460 
2a 1.4 ± 0.1 1.4 ± 0.1 1.1 ± 0.1 
2b 2.5 ± 0.1 2.5 ± 0.3 2.3 ± 0.1 
2c 46.8 ± 4.0 83.5 ± 5.8 45.0 ± 1.4 
a
 The lowest concentrations causing 50% of cell growth inhibition (GI50) after a continuous exposure of 48 h, expressed as 
means ± SEM of three independent experiments performed in duplicate. Doxorubicin was used as positive control (GI50: 
MCF-7 = 43.3 ± 2.6 nM; A375-C5 = 130.2 ± 10.1 nM; NCI-H460 = 35.6 ± 1.6 nM). 
 
 
Due to the antitumoral potential of the di(hetero)arylethers 2a–b and as both are fluorescent, 
their photophysical properties were studied. Also, their encapsulation in nanoliposomes for 
future drug delivery purposes was monitored using the intrinsic fluorescence of the 
compounds. 
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3.3. Fluorescence studies in several solvents 
The absorption and fluorescence properties of compounds 2a and 2b were studied in several 
solvents (Table 2). The normalized fluorescence spectra of both compounds are shown in 
Figures 1 and 2, respectively. Examples of absorption spectra are shown as insets. 
Compounds 2a and 2b exhibit reasonable fluorescence in several solvents. Fluorescence 
quantum yield values are in the range of 3% in chloroform and 34% in DMSO for compound 
2a and of 2% (chloroform) and 29% (DMSO) for compound 2b (Table 2). However, no 
emission is observed in protic solvents, like water or ethanol. This behaviour can be due to 
specific solute-solvent interactions by hydrogen bonds with protic solvents, namely by 
protonation of the N atom of the pyridine ring. The same explanation can justify the low 
fluorescence quantum yields obtained in chloroform, as the formation of hydrogen bonds 
between chloroform and proton acceptor molecules is known since a long time [29]. 
 
Table 2. Maximum absorption (λabs) and emission wavelengths (λem), molar absorption coefficients (ε) and 
fluorescence quantum yields (ΦF) for compounds 2a and 2b in several solvents. 
a
 Relative to quinine sulfate in H2SO4 0.05 M (ΦF  = 0.546 at 25 ºC [16]). Error about 10%. 
b Solvents cut-off: Dimethylsulfoxide: 270 nm; N,N-Dimethylformamide: 275 nm; Ethyl acetate: 265 nm; 
Chloroform: 250 nm. 
Solvent 
λabs (nm) (ε/104 M-1 cm-1) λem (nm) ΦF a 
2a 2b 2a 2b 2a 2b 
Cyclohexane 
359 (0.37), 
310 (0.54), 
288 (3.07) 
360 (0.39), 
311 (0.61), 
289 (3.06) 
425 427 0.26 0.29 
Dioxane 360 (0.55); 289 (3.69) 
361 (0.46), 
289 (3.00) 440 441 0.27 0.28 
Ethyl acetate b 
355 (0.50), 
309 (0.77), 
287 (3.40) 
361 (0.45), 
312 (0.71) 
 288 (3.02) 
448 453 0.07 0.09 
Dichloromethane 
354 (0.58), 
310 (0.89), 
288 (3.49) 
355 (0.45), 
311 (0.69), 
288 (2.80) 
447 451 0.13 0.16 
N,N-Dimethylformamide b 358 (0.56), 289 (3.39) 
357 (0.59), 
290 (3.02) 465 470 0.20 0.12 
Dimethylsulfoxide b 362 (0.62), 290 (3.42) 
364 (0.47), 
291 (2.71) 475 479 0.34 0.29 
Acetonitrile 
354 (0.55), 
309 (0.84), 
286 (3.46) 
355 (0.38), 
310 (0.60), 
287 (2.48) 
459 461 0.14 0.12 
Chloroform b 
354 (0.57), 
311 (0.91), 
289 (3.50) 
361 (0.46), 
313 (0.87) 
 290 (2.88) 
445 448 0.03 0.02 
Ethanol 
359 (0.56), 
310 (0.88), 
288 (3.72) 
361 (0.41), 
311 (0.77), 
289 (2.83) 
--- --- --- --- 
Methanol 
358 (0.56), 
310 (0.89), 
287 (3.69) 
361 (0.46); 
288 (3.06) --- --- --- --- 
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Figure 1. Normalized fluorescence spectra of 3×10-6 M solutions of compound 2a in several solvents 
(λexc=360 nm). Inset: Absorption spectrum of 2×10-5 M solutions of 2a in acetonitrile and 
dimethylformamide, as examples. 
 
 
Figure 2. Normalized fluorescence spectra of 3×10-6 M solutions of compound 2b in several solvents 
(λexc=355 nm). Inset: Absorption spectrum of 2×10-5 M solutions of 2b in acetonitrile and 
dimethylformamide, as examples. 
 
 
For both compounds, significant red shifts are observed for emission in polar solvents (50 
nm between cyclohexane and dimethylsulfoxide for compound 2a and 52 nm for 2b). In the 
absorption spectra, the red shifts are negligible (Table 2), indicating that solvent relaxation 
after photoexcitation plays an important role. In polar solvents, a clear band enlargement in 
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emission is also observed (Figs. 1 and 2), which is usually related to an intramolecular charge 
transfer (ICT) mechanism and/or to specific solvent effects [18].  
The solvatochromic plots for compounds 2a–b, shown in Figure 3, are reasonably linear, the 
slope being larger for compound 2b. This shows that the presence of the methoxy group in the 
meta position causes an enhance of the ICT character of the excited state. 
 
 
Figure 3. Solvatochromic plots (equation 4) for compounds 2a and 2b. Solvents: 1 - cyclohexane; 2 - 
dioxane; 3 - chloroform; 4 - ethyl acetate; 5 - dichloromethane; 6 - dimethylsulfoxide; 7 - N,N-
dimethylformamide; 8 - acetonitrile (values of ε and n were obtained from ref. [30]). 
 
From ab initio molecular quantum chemistry calculations, obtained with Gaussian 09 
software [31] and use of a 6-311+G(dp) basis set at the TD-SCF DFT (B3LYP) level of 
theory [32] in gas phase, the cavity radius (R) and the ground state dipole moment (µg) were 
determined for the two compounds (Table 3). The optimized geometry of the ground state of 
the di(hetero)arylethers 2a-b shows that the methoxyphenyl moiety is completely out of the 
plane of the thienopyridine system. In the lowest excited state a distortion occurs, which is 
much more pronounced in compound 2b, where the two moieties are further apart (Figure 4). 
The directions of the calculated dipole moments in the ground and excited state are also 
indicated in Figure 4, evidencing a change in the excited state dipole moment vector to almost 
the opposite direction relative to the ground state one. This clearly indicates that the angle 
between the two dipole moment vectors cannot be neglected and must be considered in the 
solvatochromic plots (Bakhshiev’s equation (4)).  
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Figure 4. Optimized geometries of compounds 2a and 2b obtained by Gaussian 09 software (grey: C 
atoms; white: H atoms; red: O atoms; blue: N atoms; yellow: S atoms). Left: ground state; Right: 
lowest excited singlet state. The arrows indicate the direction of the dipole moment. 
 
The absolute value of the difference in the excited and ground state dipole moment vectors, 
estimated from the solvatochromic plots (Figure 3) and from molecular quantum mechanical 
calculations, are presented in Table 3. The obtained values are similar and, therefore, both 
methods point to the presence of a significant charge transfer mechanism in the excited state, 
more pronounced for compound 2b. 
 
Table 3. Cavity radius (R), ground (µg) and excited state (µe) dipole moments obtained from 
theoretical calculations, and absolute value of the dipole moment difference ( ge µ−µ rr ), from quantum 
mechanical calculations and from the solvatochromic plots. 
Compound 
Cavity 
radius, R 
(Å) 
Ground state 
dipole moment, 
µg (D) 
Excited state dipole 
moment, µe (D), from 
theoretical 
calculations 
ge µ−µ
rr
 
(D) 
from theoretical 
calculations 
ge µ−µ
rr
 (D) from 
solvatochromic 
plots
 
2a 5.4 2.8 4.7  7.1 6.5 
2b 5.8 4.7 3.4  7.7 7.2 
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Figure 5 displays the representation of HOMO and LUMO molecular orbitals for the two 
compounds, obtained with the calculated optimized geometries for the ground and the lowest 
excited singlet state. It can be observed that the HOMO and LUMO molecular orbitals are 
mainly located in the thieno[3,2-b]pyridine system, with a small contribution of the ether 
oxygen atom. The HOMO-LUMO transition (for both geometries) of these compounds shows 
a significant charge transfer from the amine group linked to the thiophene ring and from its S 
atom to the pyridine moiety. A charge density decrease in the oxygen atom of the carbonyl 
group is also observed in the HOMO-LUMO transition. This confirms the CT character of the 
excited state for both compounds. 
 
 
Figure 5. Representation of HOMO and LUMO molecular orbitals of the di(hetero)arylethers 2a 
(above) and 2b (below). Left: Optimized geometry for the ground state; Right: Optimized geometry 
for the lowest excited singlet state. 
 
 
The photophysical behavior of both compounds shows that they can be considered as 
solvatochromic probes. The significant sensitivity of the fluorescence emission to the 
fluorophore environment can be very useful when probing the location/behavior of these 
compounds in liposomes. 
 
3.4. Fluorescence studies in nanoliposomes 
Fluorescence experiments of both compounds encapsulated in liposomes of several 
compositions were carried out. These liposomes were composed either by neat phospholipids, 
or by phospholipid mixtures, with or without cholesterol (Ch) and PEG. Several different 
lipid compositions were studied, keeping in mind future drug delivery applications of 2a and 
2b as potential anticancer drugs. 
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First, liposomes of neat DPPC (zwitterionic), DMPG (anionic), DODAB (cationic) and Egg-
PC (zwitterionic, composed of a phosphatidyl choline mixture) with encapsulated compounds 
were prepared and fluorescence emission was monitored in both gel (below the melting 
temperature, Tm) and liquid-crystalline (above Tm) phases of the lipid. At room temperature, 
the phospholipids DPPC and DODAB are in ordered gel phase, where the hydrocarbon chains 
are fully extended and closely packed. DMPG has a melting transition temperature very near 
room temperature (Tm = 23 ºC). The melting transition temperature of Egg-PC is very low 
[33] and this lipid is in the fluid liquid-crystalline phase at room temperature. Fluorescence 
spectra of compounds 2a-b incorporated in these liposomes are presented in Figure 6. The 
maximum emission wavelengths in Egg-PC and DPPC lipid membranes point to a 
hydrophobic environment for both compounds in lipid membranes (Figure 6, Table 4). In 
DODAB and DMPG aggregates, a band enlargement and a shift to higher emission 
wavelengths is observed, indicating a more hydrated environment for the compounds in these 
aggregates. The red shift is more significant for both compounds in DMPG aggregates, which 
can be explained by the formation of DMPG unilamellar vesicles with perforations [34], or 
leaky vesicles [35], where the compounds may feel more penetration of water molecules. 
 
 
Figure 6. Normalized fluorescence spectra of compounds 2a and 2b (3×10-6 M) in lipid aggregates of 
Egg-PC, DPPC, DMPG and DODAB, below (17 ºC or 25 ºC) and above (50 ºC) the melting 
temperature of the lipids. 
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Table 4. Steady-state fluorescence anisotropy (r) values and maximum emission wavelengths (λem) for 
compounds 2a and 2b in lipid aggregates, below (17 ºC or 25 ºC) and above (50 ºC) transition temperature of the 
lipids. Anisotropy values in glycerol at room temperature are also shown for comparison. 
  Lipid T (º C) Compound 2a Compound 2b 
λem (nm) r λem (nm) r 
Egg-PC 25 433 0.121 436 0.120 
DPPC 
25 432 0.196 433 0.186 
50 432 0.095 434 0.075 
DODAB 25 439 0.179 437 0.155 50 438 0.115 436 0.112 
DMPG 17 443 0.147 447 0.154 
50 442 0.105 446 0.108 
Glycerol 25 420 0.295 418 0.309 
 
Fluorescence anisotropy (r) measurements (Table 4) can give relevant information about the 
location of the compounds in liposomes, as r increases with the rotational correlation time of 
the fluorescent molecule (and, thus, with the viscosity of the fluorophore environment) [36]. 
Anisotropy values in a viscous solvent (glycerol) were also determined, for comparison. 
Steady-state fluorescence anisotropy results (Table 4) allow concluding that both compounds 
are mainly located in the inner region of the lipid membrane, feeling the penetration of water 
molecules, especially in DMPG aggregates. The transition from the rigid gel phase to the fluid 
liquid-crystalline phase is clearly detected by a notable decrease in anisotropy at 50 ºC. The r 
values in Egg-PC liposomes at 25 ºC (fluid phase) are also significantly lower than those 
observed in lipids which are in the gel phase at this temperature.  
Considering future developments of these compounds delivery using nanoliposomes as drug 
carriers, several different liposome formulations were prepared [37-39], some of them 
containing cholesterol (Ch) and polyethylene glycol (PEG). The incorporation of Ch may 
increase the stability by modulating the fluidity of the lipid bilayer, preventing crystallization 
of the phospholipid acyl chains and providing steric hindrance to their movement. Further 
advances in liposome research found that PEG, which is inert in the body, allows longer 
circulatory life of the drug delivery system [7].  
Previous studies have shown that DODAB-based liposomes exhibit very large sizes 
(diameter larger than 250 nm) [39-41] and, for this reason, this cationic lipid was not used in 
the liposome formulations prepared. On the contrary, most of the nanoliposomes contain 
DMPG, as the presence of pores across this lipid membrane has a promising biological 
relevance in applications for controlled release from nanocompartments [34]. 
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The size and size distribution (polydispersity index) of the prepared nanoliposomes with 
encapsulated compounds 2a and 2b were obtained by DLS. All the liposomes have a mean 
hydrodynamic diameter lower than 140 nm and generally low polydispersity (Table 5). The 
Egg-PC:Ch (7:3), Egg-PC:Ch:DMPG (7:3:1) and DSPC:Ch:DSPE-PEG2000 (1:1:0.75) 
formulations allowed us to obtain the smaller nanoliposome diameters, which are lower than 
100 nm for both compounds. The Egg-PC:Ch formulation is the one with a lower 
polydispersity. 
 
 
Table 5. Mean hydrodynamic diameter and polydispersity of several nanoliposome formulations with 
encapsulated compounds 2a and 2b, at 25 ºC. 
 
 
  Formulation 
Compound 2a Compound 2b 
Hydrodynamic 
diameter (nm) 
(mean ± SD) 
Polydispersity  
(mean ± SD) 
Hydrodynamic 
diameter (nm) 
(mean ± SD) 
Polydispersity  
(mean ± SD) 
Egg-PC:Ch (7:3) 84.4 ± 0.4 0.19 ± 0.01 87.8 ± 0.4 0.21 ± 0.01 
Egg-PC:Ch:DMPG (7:3:1) 81.2 ± 0.5 0.26 ± 0.01 90.2 ± 0.5 0.36 ± 0.02 
DPPC:DMPG (1:1) 133.4 ± 0.6 0.34 ± 0.01 116.2 ± 0.6 0.42 ± 0.02 
DPPC:DMPG (1:2) 131.7 ± 0.6 0.43 ± 0.02 141.0 ± 0.4 0.24 ± 0.01 
DPPC:DMPG (2:1) 125.6 ± 0.5 0.39 ± 0.02 114.1 ± 0.4 0.34 ± 0.01 
DSPC:DMPG (5:1) 117.4 ± 0.5 0.34 ± 0.01 136.3 ± 0.6 0.35 ± 0.01 
DSPC:Ch:DSPE-PEG2000 
(1:1:0.75) 83.6 ± 0.4 0.31 ± 0.01 71.7 ± 0.3 0.28 ± 0.01 
Standard deviations (SD) were calculated from the mean of the data of a series of five experiments conducted 
using the same parameters. 
 
 
 
The two compounds show significant fluorescence emission when incorporated in 
nanoliposomes (Figure 7) and steady-state fluorescence anisotropy values are generally high 
at room temperature (Table 6). 
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Figure 7. Normalized fluorescence spectra of compounds 2a and 2b (3×10-6 M) in nanoliposomes of 
different compositions at room temperature. 
 
 
Table 6. Steady-state fluorescence anisotropy (r) values and maximum emission wavelengths (λem) for 
compounds 2a and 2b encapsulated in nanoliposomes, at 25 ºC and 50 ºC. 
  Formulation 
 Compound 2a Compound 2b 
 λem (nm) r λem (nm) r 
Egg-PC:Ch (7:3) 25 435 0.117 439 0.109 
Egg-PC:Ch:DMPG (7:3:1) 25 434 0.176 441 0.149 50 433 0.121 442 0.109 
DPPC:DMPG (1:1) 25 445 0.239 452 0.184 50 444 0.144 443 0.108 
DPPC:DMPG (1:2) 25 444 0.220 445 0.176 50 443 0.147 446 0.125 
DPPC:DMPG (2:1) 25 447 0.213 447 0.176 50 437 0.143 437 0.116 
DSPC:DMPG (5:1) 25 458 0.215 457 0.210 50 458 0.200 457 0.196 
DSPC:Ch:DSPE-PEG2000 (1:1:0.75) 25 440 0.216 448 0.185 50 437 0.133 449 0.136 
  
 
Upon increasing temperature, both compounds exhibit a significant decrease in fluorescence 
anisotropy (Table 6), feeling an increase in fluidity of the nanoliposome membranes at high 
temperature. Therefore, both compounds are mainly located in the nanoliposome membranes. 
The decrease in r values at 50 ºC is low in DSPC:DMPG (5:1) vesicles, due to the higher 
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melting transition temperature of DSPC (Tm = 55 ºC [13]), as this phospholipid is still in the 
gel phase at 50 ºC. This fact can also contribute to the more hydrated environment reported by 
these compounds in DSPC:DMPG liposomes, as the rigidity of these membranes can prevent 
the compounds to penetrate more deeper in the lipid membranes. Overall, these results 
indicate that both compounds can be transported in the hydrophobic region of the lipid 
bilayers. 
 
4. Conclusions 
New fluorescent methoxylated di(hetero)aryl ethers in the thieno[3,2-b]pyridine series, 2a-c, 
were prepared by a copper-catalyzed Ullmann-type C-O coupling in moderate to good yields, 
using an amino acid as the ligand.  
Cell growth inhibition assays showed that compounds 2a and 2b are promising as 
antitumoral drugs, presenting very low GI50 values in the three human tumor cell lines tested. 
Both compounds have reasonable fluorescence quantum yields and can be considered as 
solvatochromic probes.  
Our experimental results in nanoliposomes suggest that both compounds can be transported 
in the hydrophobic region of the lipid bilayer. The Egg-PC:Ch (7:3), Egg-PC:Ch:DMPG 
(7:3:1) and DSPC:Ch:DSPE-PEG2000 (1:1:0.75) nanoliposomes are the best formulations for 
encapsulation of these thienopyridines, considering the size (diameter lower than 100 nm) and 
polydispersity. These results may be important for future drug delivery applications of these 
new potential antitumoral aryletherthienopyridines, using nanoliposomes as drug carriers. 
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